Integrase inhibitors: a clinical review of raltegravir and elvitegravir.
Grant
Philip
P
Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA 94305-5107, USA. pmgrant@stanford.edu
Zolopa
Andrew
A
D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D024882:Drug Resistance, Viral / Q000235:genetics; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects* / Q000201:enzymology; D015658:HIV Infections / Q000188:drug therapy*; D019427:HIV Integrase / Q000187:drug effects; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D011760:Pyrrolidinones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015363:Quinolones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000068898:Raltegravir Potassium
D017320:HIV Protease Inhibitors; D011760:Pyrrolidinones; D015363:Quinolones; D000068898:Raltegravir Potassium; C509700:elvitegravir; D019427:HIV Integrase